{"id":"https://openalex.org/W4362595892","doi":"https://doi.org/10.1158/1538-7445.am2023-5973","title":"Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer","display_name":"Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer","publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4362595892","doi":"https://doi.org/10.1158/1538-7445.am2023-5973"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2023-5973","doi":"https://doi.org/10.1158/1538-7445.am2023-5973","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-5973","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101745371","display_name":"Yue Zou","orcid":"https://orcid.org/0000-0002-2568-1442","observed_orcids":["https://orcid.org/0000-0002-2568-1442"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yue Zou","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034053795","display_name":"Srijita Dhar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srijita Dhar","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kirsten Gallagher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kirsten Gallagher","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016199329","display_name":"Andrew W. Buesking","orcid":"https://orcid.org/0000-0002-3297-9837","observed_orcids":["https://orcid.org/0000-0002-3297-9837"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Buesking","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045550674","display_name":"Sarah B. Pawley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Pawley","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102508579","display_name":"Ryan Holmes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Holmes","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100617567","display_name":"Xiaowei Wu","orcid":"https://orcid.org/0000-0003-4176-7198","observed_orcids":["https://orcid.org/0000-0003-4176-7198"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaowei Wu","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077603379","display_name":"Katarina Rohlfing","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katarina Rohlfing","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100340993","display_name":"Min Wang","orcid":"https://orcid.org/0009-0004-3693-3619","observed_orcids":["https://orcid.org/0009-0004-3693-3619"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Min Wang","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004443645","display_name":"Joseph D. Rager","orcid":"https://orcid.org/0009-0004-6008-9630","observed_orcids":["https://orcid.org/0009-0004-6008-9630"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Rager","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113149839","display_name":"Tom Emm","orcid":"https://orcid.org/0009-0006-0288-9626","observed_orcids":["https://orcid.org/0009-0006-0288-9626"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tom Emm","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048703920","display_name":"Stefan U. Ruepp","orcid":"https://orcid.org/0009-0008-7476-7614","observed_orcids":["https://orcid.org/0009-0008-7476-7614"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Ruepp","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034085965","display_name":"Miles Cowart","orcid":"https://orcid.org/0009-0006-1839-9242","observed_orcids":["https://orcid.org/0009-0006-1839-9242"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Miles Cowart","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056760841","display_name":"Jing Ni","orcid":"https://orcid.org/0000-0002-4229-775X","observed_orcids":["https://orcid.org/0000-0002-4229-775X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Ni","raw_affiliation_strings":["2Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043714628","display_name":"Jean J. Zhao","orcid":"https://orcid.org/0000-0002-4561-5688","observed_orcids":["https://orcid.org/0000-0002-4561-5688"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean Zhao","raw_affiliation_strings":["2Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036665836","display_name":"Bruce Ruggeri","orcid":"https://orcid.org/0009-0002-0095-873X","observed_orcids":["https://orcid.org/0009-0002-0095-873X"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce Ruggeri","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022438790","display_name":"Andrew P. Combs","orcid":"https://orcid.org/0000-0003-1418-5168","observed_orcids":["https://orcid.org/0000-0003-1418-5168"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Combs","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046355139","display_name":"Kris Vaddi","orcid":"https://orcid.org/0009-0009-8581-6511","observed_orcids":["https://orcid.org/0009-0009-8581-6511"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kris Vaddi","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004633647","display_name":"Sandy Geeganage","orcid":"https://orcid.org/0009-0002-4608-8012","observed_orcids":["https://orcid.org/0009-0002-4608-8012"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandy Geeganage","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080610604","display_name":"Ashish Juvekar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ashish Juvekar","raw_affiliation_strings":["3Modifi Bio, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Modifi Bio, New Haven, CT","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100460365","display_name":"Sang\u2010Hyun Lee","orcid":"https://orcid.org/0000-0002-8847-183X","observed_orcids":["https://orcid.org/0000-0002-8847-183X"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sang Hyun Lee","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018193992","display_name":"Peggy Scherle","orcid":"https://orcid.org/0000-0003-0783-6815","observed_orcids":["https://orcid.org/0000-0003-0783-6815"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peggy Scherle","raw_affiliation_strings":["1Prelude Therapeutics Inc., Wilmington, DE;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics Inc., Wilmington, DE;","institution_ids":["https://openalex.org/I4405265449"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"7_Supplement","first_page":"5973","last_page":"5973"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9312000274658203,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9312000274658203,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.01899999938905239,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.013799999840557575,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9629999995231628},{"id":"https://openalex.org/keywords/brain-penetrant-drugs","display_name":"brain-penetrant drugs","score":0.8090000152587891},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9229999780654907},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.9010000228881836},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.8040000200271606},{"id":"https://openalex.org/keywords/kras-g12c-inhibitors","display_name":"KRAS G12C inhibitors","score":0.8999999761581421},{"id":"https://openalex.org/keywords/ras-mek-erk-pathway","display_name":"Ras/MEK/ERK pathway","score":0.8569999933242798},{"id":"https://openalex.org/keywords/cdkn2a-deletion","display_name":"CDKN2A deletion","score":0.8460000157356262},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6740000247955322}],"concepts":[{"id":"https://openalex.org/C199649820","wikidata":"https://www.wikidata.org/wiki/Q14911762","display_name":"Cyclin-dependent kinase 6","level":5,"score":0.8277360200881958},{"id":"https://openalex.org/C124320809","wikidata":"https://www.wikidata.org/wiki/Q46292","display_name":"Cyclin-dependent kinase","level":4,"score":0.6600732803344727},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5951327681541443},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5302215218544006},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.5211851000785828},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.5173425078392029},{"id":"https://openalex.org/C120504264","wikidata":"https://www.wikidata.org/wiki/Q1147372","display_name":"Cyclin-dependent kinase 1","level":4,"score":0.4971804916858673},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4740737974643707},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4369314908981323},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41467615962028503},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.396680623292923},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3365703821182251},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.321111261844635},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.279535710811615},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2225199043750763},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.15457379817962646}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2023-5973","doi":"https://doi.org/10.1158/1538-7445.am2023-5973","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-5973","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393087067","https://openalex.org/W4282945463","https://openalex.org/W4389242120","https://openalex.org/W2887177266","https://openalex.org/W2954222118","https://openalex.org/W7149127498","https://openalex.org/W3006710845","https://openalex.org/W2775259666","https://openalex.org/W4409629752","https://openalex.org/W2399361760"],"abstract_inverted_index":{"Abstract":[0],"Cell":[1],"cycle":[2,74],"deregulation":[3],"is":[4,445],"a":[5,109,141,294,318,373],"hallmark":[6],"of":[7,14,19,31,45,70,78,92,137,146,182,190,213,219,291,349,457,467],"cancer":[8,20,102,323,463],"and":[9,12,25,37,43,57,76,96,125,131,139,155,162,169,226,247,279,337,356,371,381,460,480],"the":[10,40,79,90,188,220,260,280,468],"hyperactivation":[11],"overexpression":[13],"CDKs":[15],"are":[16,28,87,97],"often":[17],"drivers":[18],"pathogenesis.":[21],"Cyclin-dependent":[22],"kinase":[23,299,335],"4":[24],"6":[26],"(CDK4)/(CDK6)":[27],"critical":[29],"mediators":[30],"cellular":[32,135,144],"transition":[33],"into":[34,386],"S":[35],"phase":[36],"important":[38],"for":[39,89,305,471],"initiation,":[41],"growth,":[42],"survival":[44,340],"many":[46],"cancers.":[47],"Activated":[48],"CDK4/CDK6":[49,85,113,124],"complexes":[50,62],"phosphorylate":[51],"Rb1,":[52],"reduce":[53],"their":[54],"binding":[55],"affinities":[56],"release":[58],"Rb1-containing":[59],"transcription":[60,65],"repressor":[61],"from":[63],"E2F":[64,71],"factors,":[66],"resulting":[67],"in":[68,100,179,192,199,210,223,251,276,331,448,454],"activation":[69,218],"controlled":[72],"cell":[73,80,214],"genes":[75],"progression":[77],"cycle.":[81],"At":[82],"present":[83],"three":[84],"inhibitors":[86,275],"approved":[88,236,303],"treatment":[91,208,304],"ER+/HER2-":[93,183],"breast":[94,184,310,322,462],"cancer,":[95,185,311],"being":[98],"explored":[99,187,289],"other":[101,193,202,451],"indications":[103],"as":[104,196,198],"well.":[105],"Previously":[106],"we":[107,186,288],"described":[108],"novel":[110],"brain":[111,160,295,315,324,357,374,440],"penetrant":[112,296,375,441],"inhibitor,":[114],"PRT3645,":[115,444],"that":[116,216,258],"exhibits":[117,140,150],"single":[118],"digit":[119],"nanomolar":[120],"biochemical":[121],"potency":[122],"against":[123,128],">2000-fold":[126],"selectivity":[127],"CDK1,":[129],"CDK2":[130],"CDK9.":[132],"PRT3645":[133,149,191,207,243,270,292,327,344,362,383],"inhibits":[134],"phosphorylation":[136],"Rb":[138],"protein":[142],"binding-adjusted":[143],"IC50":[145],"<300":[147],"nM.":[148],"favorable":[151],"in-vitro":[152,380],"safety":[153],"pharmacology":[154],"ADME":[156],"properties,":[157],"including":[158,312],"increased":[159],"penetration,":[161],"demonstrates":[163,345],"oral":[164,242],"bioavailability":[165],"across":[166,354],"rodents,":[167],"dog,":[168],"non-human":[170],"primates.":[171],"In":[172,205,286,317,342,359],"addition":[173],"to":[174],"robust":[175],"monotherapy":[176],"activity":[177,189],"observed":[178],"preclinical":[180,360,455],"models":[181,257,278,456],"tumor":[194],"types":[195],"well":[197,245,284],"combination":[200,281,332,449],"with":[201,234,273,293,307,314,333,368,372,450],"targeted":[203,452],"therapies.":[204],"NSCLC,":[206,458],"resulted":[209],"significant":[211],"inhibition":[212,336],"lines":[215],"harbor":[217,259],"RAS/MEK/ERK":[221],"pathway":[222],"proliferation":[224],"assays":[225],"demonstrated":[227],"comparable":[228],"high":[229],"synergy":[230],"scores":[231],"when":[232,269,366],"combined":[233,272,367],"clinically":[235],"covalent":[237],"KRAS":[238,253],"G12C":[239,254],"inhibitors.":[240],"In-vivo,":[241],"was":[244,266,271,283,328,363],"tolerated":[246],"induced":[248],"anti-tumor":[249],"efficacy":[250,265],"two":[252],"mutant":[255],"xenograft":[256,277],"CDKN2A":[261],"(p16)":[262],"deletion.":[263],"Anti-tumor":[264],"further":[267],"improved":[268],"KRAS/MEK":[274,369],"therapy":[282],"tolerated.":[285],"addition,":[287],"combinations":[290],"receptor":[297,377],"tyrosine":[298],"inhibitor":[300],"(TKI),":[301],"an":[302,346],"patients":[306,313],"advanced":[308,385],"HER2+":[309,319],"metastases.":[316],"orthotopic":[320],"human":[321],"metastasis":[325],"model,":[326],"highly":[329,364,446],"efficacious":[330,365],"HER2":[334,376],"enhanced":[338],"median":[339],"significantly.":[341],"summary,":[343],"excellent":[347],"balance":[348],"potency,":[350],"selectivity,":[351],"PK":[352],"parameters":[353],"species":[355],"penetrance.":[358],"studies,":[361],"inhibitors,":[370],"TKI,":[378],"both":[379],"in-vivo.":[382],"has":[384],"Phase":[387],"1":[388,478],"clinical":[389],"trials":[390],"(NCT05538572).":[391],"Citation":[392],"Format:":[393],"Yue":[394],"Zou,":[395],"Srijita":[396],"Dhar,":[397],"Kirsten":[398],"Gallagher,":[399],"Andrew":[400,426],"Buesking,":[401],"Sarah":[402],"Pawley,":[403],"Ryan":[404],"Holmes,":[405],"Xiaowei":[406],"Wu,":[407],"Katarina":[408],"Rohlfing,":[409],"Min":[410],"Wang,":[411],"Joseph":[412],"Rager,":[413],"Tom":[414],"Emm,":[415],"Stefan":[416],"Ruepp,":[417],"Miles":[418],"Cowart,":[419],"Jing":[420],"Ni,":[421],"Jean":[422],"Zhao,":[423],"Bruce":[424],"Ruggeri,":[425],"Combs,":[427],"Kris":[428],"Vaddi,":[429],"Sandy":[430],"Geeganage,":[431],"Ashish":[432],"Juvekar,":[433],"Sang":[434],"Hyun":[435],"Lee,":[436],"Peggy":[437],"Scherle.":[438],"The":[439],"CDK4/6":[442],"Inhibitor,":[443],"effective":[447],"therapies":[453],"CRC,":[459],"HER2-positive":[461],"[abstract].":[464],"In:":[465],"Proceedings":[466],"American":[469],"Association":[470],"Cancer":[472,491],"Research":[473],"Annual":[474],"Meeting":[475],"2023;":[476],"Part":[477],"(Regular":[479],"Invited":[481],"Abstracts);":[482],"2023":[483],"Apr":[484],"14-19;":[485],"Orlando,":[486],"FL.":[487],"Philadelphia":[488],"(PA):":[489],"AACR;":[490],"Res":[492],"2023;83(7_Suppl):Abstract":[493],"nr":[494],"5973.":[495]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2023-04-06T00:00:00"}